阿尔茨海默病生物标志物或有助于预测曾逆转为正常的轻度认知障碍患者预后
该研究基于阿尔茨海默病神经影像学倡议数据,选取随访中逆转为正常认知的轻度认知障碍患者,比较后续临床下降者与稳定逆转者的临床标志物、AD生物标志物及神经退行影像标志物。结论提示AD生物标志物可能辅助预测逆转MCI的预后。
要点
- MCI逆转为正常者中约24%在平均3.2年后再次进展为MCI。
- 后续下降者年龄更大,淀粉样蛋白PET负荷及脑脊液tau水平更高。
- AD生物标志物可能有助于曾逆转MCI患者的预后判断。
核心结论
- 在曾逆转为正常认知的MCI患者中,AD病理生物标志物异常与后续临床下降相关。
研究设计与样本
- 基于阿尔茨海默病神经影像学倡议数据,选取随访中逆转为正常认知的MCI患者,按后续临床结局分为下降组与稳定逆转组进行比较。
主要发现
- 61例有随访数据的逆转者中,平均3.2±2.2年后16例(24%)进展为MCI,3例(5%)进展为痴呆。
- 后续下降者年龄更大,淀粉样蛋白PET负荷更高,脑脊液tau水平更高。
临床怎么用
- 对曾逆转为正常认知的MCI患者,可考虑检测AD生物标志物以辅助判断后续下降风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.
引用
- Vermunt L, van Paasen AJL, Teunissen CE, et al. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. 2019. PMID: 31068481. doi:10.1212/WNL.0000000000007609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。